GLPwatch
A Study of HM11260C in Healthy Male Subject
NCT01093729 · Completed
Last updated 2026-05-28This clinical trial tests the safety of the investigational drug HM11260C in healthy adult men.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, triple-blind treatment study
Participants 41 people
Who can join Ages 20–45 · male only Healthy volunteers accepted.
Timeline Started 2010-02 · est. completion 2010-10
What this study is testing ClinicalTrials.gov NCT01093729 ↗
Description as written by the study sponsor.
Study Design: Randomized, double-blind, placebo-controlled, escalating single-dose design. Five ascending dose cohorts are planned.
Treatments tested
- HM11260C Drug
HM11260C 0.5mcg/kg or Placebo
- HM11260C Drug
HM11260C 2mcg/kg or Placebo
- HM11260C Drug
HM11260C 4mcg/kg or Placebo
- HM11260C Drug
HM11260C 8mcg/kg or Placebo
- HM11260C Drug
HM11260C 14mcg/kg or Placebo
| Main thing measured | Safety |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Conditions studied | Healthy |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01093729 ↗